LOS ANGELES--(BUSINESS WIRE)--Sept. 6, 2006--Hythiam, Inc. (NASDAQ:HYTM), a healthcare services management company that licenses the PROMETA(TM) treatment protocols designed to treat alcohol, methamphetamine and cocaine dependence, announced today that the European Patent Office has granted to Hythiam a patent for a use of a composition of matter for the treatment of alcohol dependence under European Patent Number 1374952. The patent will protect the intellectual property underlying the company’s PROMETA Protocol for alcohol dependence. With this formal grant, the European patent can be validated in 19 designated European countries.
